UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)														
1. Name and Address of Reporting Person* Berger Dietmar					2. Issuer Name and Ticker or Trading Symbol Atara Biotherapeutics, Inc. [ATRA]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900					3. Date of Earliest Transaction (Month/Day/Year) 03/26/2019							X Officer (give title below) Other (specify below) Global Head of R&D				
(Street) SOUTH SAN FRANCISCO, CA 94080				4. I	4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State) (Zip)					Table I - Non-Derivative Securities Acqu							uired, Disposed of, or Beneficially Owned				
(Instr. 3) Date			2. Transaction Date (Month/Day/Yes	Exe ar) any		(Instr. 8)		A. Securities Acqui (A) or Disposed of (Instr. 3, 4 and 5)			D) Beneficia Reported	ally Owned Following Transaction(s)		6. Ownership Form:	Beneficial	
				(Me	onth/Day/Year	Code	V	Amou	(A) or (D)			(Instr. 3 and 4)			Ownership (Instr. 4)	
Common Stock 0			03/26/2019			A		15,00	0 A	\$ 0	90,000	90,000		D		
			Table II		ivative Securiti , puts, calls, wa											
1. Title of Derivative Security (Instr. 3)		3. Transaction Date (Month/Day/Y	3A. Deeme Execution 1	(e.g., ed Date, if	f Transaction Code (Instr. 8)	arrants, o	cont the f	ained in orm dis	of, or Botible second Date	orm a current a curitie	rently valid ially Owned s) Title and mount of inderlying ecurities instr. 3 and	8. Price of	9. Number of Derivative Securities Beneficially Owned Following	of 10. Ownersh	Beneficia Ownershi : (Instr. 4)	
	Security					(A) or Disposed of (D) (Instr. 3, 4, and 5)			•			Reported Transaction(s (Instr. 4)	or Indire	ct		
						(A) (D)			Expirati Date	ion Ti	Amount or Number of Shares					
Repor	ting O	wners														
]	Relations	hips									
Reporting Owner Name / Address				Directo	10%		Othor									

Officer

Global Head of R&D

Other

Signatures

Berger Dietmar

/s/ David Tucker, Attorney-in-Fact for Dietmar Berger	03/27/2019
Signature of Reporting Person	Date

Director

Owner

Explanation of Responses:

C/O ATARA BIOTHERAPEUTICS, INC.

611 GATEWAY BLVD., SUITE 900 SOUTH SAN FRANCISCO, CA 94080

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These restricted stock units vest as to 50% of the shares on March 26, 2020 and 50% of the shares on March 26, 2021, subject to the reporting person's continuous service.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.